{
    "2021-12-20": [
        [
            {
                "time": "2023-03-15",
                "original_text": "Sandoz submits Biologics License Application for proposed biosimilar trastuzumab to US FDA",
                "features": {
                    "keywords": [
                        "Sandoz",
                        "Biologics",
                        "License",
                        "Application",
                        "biosimilar",
                        "trastuzumab",
                        "US",
                        "FDA"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-03-15",
                "original_text": "Market check: Stocks open lower, yield curve steepens, oil under pressure",
                "features": {
                    "keywords": [
                        "Market",
                        "Stocks",
                        "open",
                        "lower",
                        "yield",
                        "curve",
                        "steepens",
                        "oil",
                        "pressure"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "energy",
                        "finance"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2023-03-15",
                "original_text": "Novartis Inks Option Agreement For BeiGene Anti-Cancer Therapy For Over $1B",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Option",
                        "Agreement",
                        "BeiGene",
                        "Anti-Cancer",
                        "Therapy",
                        "$1B"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-03-15",
                "original_text": "Novartis' Ligelizumab Suffers Setback In Late-Stage Skin Disorder Studies",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Ligelizumab",
                        "Setback",
                        "Late-Stage",
                        "Skin",
                        "Disorder",
                        "Studies"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2023-03-15",
                "original_text": "BeiGene to receive up to $1 billion in oncology deal with Novartis",
                "features": {
                    "keywords": [
                        "BeiGene",
                        "receive",
                        "$1",
                        "billion",
                        "oncology",
                        "deal",
                        "Novartis"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-03-15",
                "original_text": "Novartis strengthens immunotherapy pipeline with option, collaboration and license agreement with BeiGene for TIGIT inhibitor ociperlimab",
                "features": {
                    "keywords": [
                        "Novartis",
                        "strengthens",
                        "immunotherapy",
                        "pipeline",
                        "option",
                        "collaboration",
                        "license",
                        "agreement",
                        "BeiGene",
                        "TIGIT",
                        "inhibitor",
                        "ociperlimab"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-03-15",
                "original_text": "Novartis provides an update on Phase III ligelizumab (QGE031) studies in chronic spontaneous urticaria (CSU)",
                "features": {
                    "keywords": [
                        "Novartis",
                        "update",
                        "Phase",
                        "III",
                        "ligelizumab",
                        "(QGE031)",
                        "studies",
                        "chronic",
                        "spontaneous",
                        "urticaria",
                        "(CSU)"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}